MX2023002482A - Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. - Google Patents
Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.Info
- Publication number
- MX2023002482A MX2023002482A MX2023002482A MX2023002482A MX2023002482A MX 2023002482 A MX2023002482 A MX 2023002482A MX 2023002482 A MX2023002482 A MX 2023002482A MX 2023002482 A MX2023002482 A MX 2023002482A MX 2023002482 A MX2023002482 A MX 2023002482A
- Authority
- MX
- Mexico
- Prior art keywords
- dialysis
- antagonist
- prevention
- treatment
- active ingredient
- Prior art date
Links
- 102100021596 Interleukin-31 Human genes 0.000 title abstract 3
- 101710181613 Interleukin-31 Proteins 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 238000000502 dialysis Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2020/032987 WO2022049614A1 (ja) | 2020-09-01 | 2020-09-01 | Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002482A true MX2023002482A (es) | 2023-03-08 |
Family
ID=73741045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002482A MX2023002482A (es) | 2020-09-01 | 2020-09-01 | Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230391878A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4209227A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6799831B1 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102800698B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN116096411A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020466800A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3189847A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300694A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002482A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022049614A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA43918A (fr) | 2015-04-14 | 2018-12-05 | Chugai Pharmaceutical Co Ltd | Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 |
| HRP20250972T1 (hr) | 2015-04-14 | 2025-10-10 | Chugai Seiyaku Kabushiki Kaisha | Farmaceutski pripravak za prevenciju i/ili liječenje atopijskog dermatitisa koji sadrži il-31 antagonist kao djelatni sastojak |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| EP4062933A4 (en) | 2019-11-20 | 2023-12-13 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
| WO2025167991A1 (zh) * | 2024-02-07 | 2025-08-14 | 武汉人福创新药物研发中心有限公司 | 一种靶向il-31ra的抗体或其抗原结合片段及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| ATE455852T1 (de) | 1999-06-02 | 2010-02-15 | Chugai Pharmaceutical Co Ltd | Neues hämopoietin rezeptorprotein nr10 |
| ES2335861T3 (es) | 2000-09-08 | 2010-04-06 | Universitat Zurich | Grupos de proteinas repetitivas que comprenden modulos repetitivos. |
| EP1356075A4 (en) | 2000-10-16 | 2005-04-13 | Compound Therapeutics Inc | PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| JP2002338476A (ja) * | 2001-05-21 | 2002-11-27 | Health Factor Kenkyusho:Kk | 腎透析に伴う痒みの予防治療剤 |
| US7494804B2 (en) | 2002-01-18 | 2009-02-24 | Zymogenetics, Inc. | Polynucleotide encoding cytokine receptor zcytor17 multimer |
| CA2555340A1 (en) | 2004-02-12 | 2005-09-01 | Lexicon Genetics Incorporated | Gene disruptions, compositions and methods relating thereto |
| EP1671642A1 (en) | 2004-12-15 | 2006-06-21 | Universite D'angers | Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof. |
| AU2006214325B2 (en) | 2005-02-14 | 2012-04-05 | National Jewish Medical And Research Center | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| CA2594490A1 (en) | 2005-02-14 | 2006-08-24 | Zymogenetics Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| JP5065253B2 (ja) | 2005-05-06 | 2012-10-31 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１モノクローナル抗体とその使用法 |
| CN101589060A (zh) * | 2006-01-10 | 2009-11-25 | 津莫吉尼蒂克斯公司 | 使用il-31拮抗剂在神经元性组织中治疗疼痛和炎症的方法 |
| JP2009528264A (ja) | 2006-01-10 | 2009-08-06 | ザイモジェネティクス，インコーポレイティド | Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法 |
| CA2654623C (en) | 2006-06-08 | 2016-07-26 | Chugai Seiyaku Kabushiki Kaisha | An anti-nr10/il-31ra antibody for use in preventing or treating an inflammatory disease |
| PL2594586T3 (pl) | 2006-09-01 | 2015-02-27 | Zymogenetics Inc | Przeciwciała monoklonalne IL-31 i sposoby ich zastosowania |
| KR20160074019A (ko) | 2007-12-05 | 2016-06-27 | 추가이 세이야쿠 가부시키가이샤 | 항ｎｒ１０ 항체 및 그의 이용 |
| MY185647A (en) | 2007-12-05 | 2021-05-27 | Chugai Pharmaceutical Co Ltd | Therapeutic agent for pruritus |
| CA2708251C (en) | 2007-12-07 | 2016-04-12 | Zymogenetics, Inc. | Humanized antibody molecules specific for il-31 |
| JP2010210772A (ja) | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| JP5650871B1 (ja) * | 2013-06-28 | 2015-01-07 | 中外製薬株式会社 | そう痒を伴う疾患に罹患した患者のｉｌ−３１アンタゴニストによる治療に対する応答を予測する方法 |
| WO2015025767A1 (ja) * | 2013-08-21 | 2015-02-26 | 久光製薬株式会社 | 貼付剤 |
| US20190135804A1 (en) * | 2017-11-03 | 2019-05-09 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Compositions and methods for the inhibition of pruritus |
| KR102156932B1 (ko) * | 2017-11-23 | 2020-09-17 | 주식회사 헬릭스미스 | 천연추출물을 포함하는 소양증의 예방 또는 치료용 조성물 |
| JP2021522241A (ja) * | 2018-04-25 | 2021-08-30 | キニクサ ファーマシューティカルズ， リミテッド | 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療 |
-
2020
- 2020-09-01 WO PCT/JP2020/032987 patent/WO2022049614A1/ja not_active Ceased
- 2020-09-01 US US18/023,246 patent/US20230391878A1/en active Pending
- 2020-09-01 IL IL300694A patent/IL300694A/en unknown
- 2020-09-01 KR KR1020217018823A patent/KR102800698B1/ko active Active
- 2020-09-01 MX MX2023002482A patent/MX2023002482A/es unknown
- 2020-09-01 EP EP20952354.7A patent/EP4209227A4/en active Pending
- 2020-09-01 CA CA3189847A patent/CA3189847A1/en active Pending
- 2020-09-01 KR KR1020207030800A patent/KR102269716B1/ko active Active
- 2020-09-01 AU AU2020466800A patent/AU2020466800A1/en active Pending
- 2020-09-01 CN CN202080103639.6A patent/CN116096411A/zh active Pending
- 2020-09-01 JP JP2020551453A patent/JP6799831B1/ja active Active
- 2020-11-11 JP JP2020187708A patent/JP7548784B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022041802A (ja) | 2022-03-11 |
| JPWO2022049614A1 (cg-RX-API-DMAC7.html) | 2022-03-10 |
| IL300694A (en) | 2023-04-01 |
| WO2022049614A1 (ja) | 2022-03-10 |
| EP4209227A4 (en) | 2024-05-29 |
| KR102269716B1 (ko) | 2021-06-28 |
| EP4209227A1 (en) | 2023-07-12 |
| JP7548784B2 (ja) | 2024-09-10 |
| AU2020466800A1 (en) | 2023-03-23 |
| KR20230048233A (ko) | 2023-04-11 |
| US20230391878A1 (en) | 2023-12-07 |
| KR102800698B1 (ko) | 2025-04-24 |
| CA3189847A1 (en) | 2022-03-10 |
| JP6799831B1 (ja) | 2020-12-16 |
| CN116096411A (zh) | 2023-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002482A (es) | Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
| BR112021009595A2 (pt) | Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres | |
| BR112022000503A2 (pt) | Compostos úteis para tratar infecções por vírus influenza | |
| MX2019014104A (es) | Compuesto novedoso de bifenilo o sal del mismo. | |
| CL2021000741A1 (es) | Composiciones plaguicidas sinérgicas y métodos para distribución de ingredientes activos insecticidas | |
| NZ735820A (en) | Compositions comprising a combination of an anti-pd-1 antibody and another antibody | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| BR112014016672A8 (pt) | compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo | |
| CR20150505A (es) | Derivado de dihidropiridazin-3,5-diona | |
| CL2021001739A1 (es) | Inhibidores de la proteína de activación de fibroblastos. | |
| BR112022004677A2 (pt) | Composição oftálmica para o tratamento de uveíte | |
| BR112022002289A2 (pt) | Composições de curativo líquido e seus usos veterinários | |
| ECSP21067816A (es) | Formulaciones farmacéuticas | |
| BR112021025732A2 (pt) | Inibidores macrocíclicos de mcl-1 | |
| CO2017011778A2 (es) | Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden | |
| MX388378B (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos. | |
| MX2020012989A (es) | Agente terapeutico para la fibrosis. | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| MX2023010491A (es) | Composicion farmaceutica para el tratamiento o la prevencion de la miastenia gravis. | |
| BR112017004505A2 (pt) | agente terapêutico e método para prevenção e/ou tratamento de incontinência urinária, e, composto ou um sal do mesmo. | |
| BR112021022194A2 (pt) | Formulações líquidas para dosagem oral de metilnaltrexona | |
| BR112017021380A2 (pt) | composto, combinação, formulação farmacêutica, método de extermínio e/ou prevenção do crescimento de um protozoário, e, uso de composto | |
| BR112017023425A2 (pt) | combinações terapêuticas de terapias antivirais e anti-inflamatórias | |
| KR102412352B9 (ko) | ERR-α 억제제를 유효성분으로 하는 백혈병 치료용 약학 조성물 | |
| MX2019008338A (es) | Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco. |